Effect of Deferasirox Chelation on Liver Iron and Total Body Iron Concentration
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
To determine efficacy of Deferasirox (DFX) on total body iron and liver iron concentration (LIC) as estimated by serum ferritin (SF) and liver MRI T2*.
Thirty patients had baseline MRI T2* of the liver performed to determine LIC before starting DFX therapy and classified as normal >6.3 milliseconds (ms), mild 6.3−2.7 ms, moderate 2.7−1.4 ms and severe iron overload <1.4 ms. DFX was given 25–35 mg/kg/d. The serum ferritin (SF) level was estimated every 3 monthly. Liver iron is expressed as liver R2* = 1000/T2*. The primary end point of the study was to determine change in SF and liver MRI R2* values after 18 mo of therapy.
All 30 patients had some degree of liver iron overload; 11 (36.6 %) had severe, 15 (50 %) had moderate while 4 (13.3 %) had mild overload. The pre-DFX therapy median SF of all was 3604.5 ng/mL (IQR 2357.0–5056.0) and median liver R2* was 574.71 Hz (IQR 411.3–770.8). After 18 mo, SF dropped significantly to a median of 2036.5 ng/mL (IQR 1700.0–3162.0) (p = 0.0011), while median liver R2* decreased from 574.71 to 568.18Hz (IQR 393.4–803.2) which was not significant (p = 0.986).
DFX monotherapy at the doses used decreases total body iron, but does not significantly decrease liver iron. It is well tolerated by Indian thalassemia patients, with observed side effects including rash, diarrhea, and transient albuminuria. MRI T2* (and derived R2*) can serve as useful method in non invasive monitoring of LIC in thalassemia patient management.
- Borgda-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89:1187–93.
- Angelucci E, Brittenham GM, Mclaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med. 2000;343:327–31. CrossRef
- Tziomalos K, Perifanis V. Liver iron content determination by magnetic resonance imaging. World J Gastroenterol. 2010;16:1587–97. CrossRef
- Wood JC. Diagnosis and management of transfusion iron overload: The role of imaging. Am J Hematol. 2007;82:1132–5. CrossRef
- Butensky E, Fischer R, Hudes M, et al. Variability in hepatic iron concentration in percutaneous needle biopsy specimens from patients with transfusional hemosiderosis. Am J Clin Pathol. 2005;123:146–52. CrossRef
- Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115:1876–84. CrossRef
- Wood JC, Kang BP, Thompson A, et al. The effect of deferasirox on cardiac iron in thalassemia major: Impact of total body iron stores. Blood. 2010;116:537–43. CrossRef
- Di Tucci AA, Matta G, Deplano S, et al. Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica. 2008;93:1385–8. CrossRef
- Wood JC. Magnetic resonance imaging measurement of iron overload. Curr Opin Hematol. 2007;14:183–90. CrossRef
- Perifanis V, Tziomalos K, Tsatra I, Karyda S, Patsiaoura K, Athanassiou-Metaxa M. Prevalence and severity of liver disease in patients with b thalassemia major. A single-institution fifteen-year experience. Haematologica. 2005;90:1136–8.
- Jean G, Terzoli S, Mauri R, et al. Cirrhosis associated with multiple transfusions in thalassaemia. Arch Dis Child. 1984;59:67–70. CrossRef
- Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron–overloaded patients with beta-thalassemia: The ESCALATOR study. Eur J Haematol. 2009;82:458–65. CrossRef
- Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107:3455–62. CrossRef
- Mazza P, Giua R, De Marco S, et al. Iron overload in thalassemia: Comparative analysis of magnetic resonance imaging, serum ferritin and iron content of the liver. Haematologica. 1995;80:398–404.
- Merchant R, Joshi A, Ahmed J, Krishnan P, Jankharia B. Evaluation of cardiac iron load by cardiac magnetic resonance in thalassemia. Indian Pediatr. 2011;48:697–701. CrossRef
- Noetzli LJ, Carson SM, Nord AS, Coates TD, Wood JC. Longitudinal analysis of heart and liver iron in thalassemia major. Blood. 2008;112:2973–8. CrossRef
- Taher A, Cappellini MD, Vichinsky E, et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol. 2009;147:752–9. CrossRef
- Vichinsky E, Bernaudin F, Forni GL, et al. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overload patients with sickle cell disease. Br J Haematol. 2011;154:387–97. CrossRef
- Effect of Deferasirox Chelation on Liver Iron and Total Body Iron Concentration
The Indian Journal of Pediatrics
Volume 80, Issue 8 , pp 655-658
- Cover Date
- Print ISSN
- Online ISSN
- Springer India
- Additional Links
- Liver iron concentration
- Liver MRI T2*/R2*
- Serum ferritin
- Industry Sectors
- Author Affiliations
- 1. Department of Pediatrics, Dr. Balabhai Nanavati Hospital, Mumbai, India
- 3. Dr. D.Y. Patil Medical College, Mumbai, India
- 4. Department of Radiology, Piramal Jhankaria Imaging and Diagnostics, Mumbai, India
- 2. 501, Rangmahal 5th floor, 2 Mount Mary road, Bandra (west), Mumbai, 400050, India